A Phase 1 interventional study of BGB-A317 and BGB-A317 in Advanced Cancer, sponsored by BeiGene. Completed at 27 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-17.
Sponsored by BeiGene · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study evaluated the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-A317 in participants with advanced tumors.
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Participants must have had a or cytologically confirmed advanced or tumor for which no effective standard therapy was available.
i. non-small cell lung cancer (participants with documented epidermal growth factor receptor mutation or anaplastic lymphoma kinase rearrangement should have been excluded) ii. ovarian cancer iii. gastric cancer iv. hepatocellular carcinoma (HCC, Barcelona-Clinic Liver Cancer stage C, stage B not amenable to locoregional therapy or to locoregional therapy, and not amenable to a curative treatment approach, and A) v. head and neck squamous cell carcinoma vi. esophageal carcinoma vii. triple negative breast cancer viii. cholangiocarcinoma ix. renal cell cancer, bladder cancer, melanoma, Merkel-cell carcinoma, sarcoma, gastrointestinal stromal tumor, or cutaneous squamous cell carcinoma. Or any other solid tumors with known microsatellite instability-high or mismatch repair deficient status, such as colorectal cancer or pancreatic cancer
Participants must have had adequate organ function as indicated by the following laboratory values:
Key Exclusion Criteria:
Active infection requiring therapy, positive tests for surface antigen or ribonucleic acid except in participant with HCC, who met the following criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may have applied.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: BGB-A317
Biological: BGB-A317
In the dose escalation part, the dose levels were escalated following a modified 3+3 dose escalation scheme. In the scheduled exploration part, participants were assigned to doses and dose schedules. In the fixed dose exploration part, participants were assigned to dose group(s) not to exceed the maximum tolerated dose. In the dose expansion part, participants were assigned to different groups based on their tumor type.
Participants were assigned to different groups based on their tumor types
Phase 1A: Number of Participants Experiencing Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of an investigational product. All AEs were monitored per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE version \[v\] 4.03 2010).
Time frame: Day -28 through 5 years and 2 months
Phase 1A: Number Of Participants With Abnormal Physical Examination Values
A complete physical examination, vital signs (systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse rate, temperature, and respiratory rate), and weight were performed pre-specified time points for Phase 1A. During the treatment period, symptom-directed physical examinations were performed. If there were no complaints and no abnormal findings from the previous visit for a particular organ system, a physical examination of that organ system was not required.
Time frame: Day 1 and Day 15 of each cycle through 30 (+/- 7) days after last dose (up to 5 years and 2 months)
Phase 1A: Number Of Participants Experiencing Dose-dependent Toxicity Through Ophthalmology Findings
Ophthalmological examinations (such as eyesight/visual acuity, fundoscopy, slit lamp microscopy, and optical coherence tomography \[or equivalent diagnostic test\]) were performed at pre-specified time points for Phase 1A. Eye exam, visual acuity test, and optical coherence tomography (or equivalent diagnostic test) will be assessed by an appropriate specialist at Screening. Participants dosed underwent subsequent ophthalmologic examinations, a specified in the protocol, by an appropriate specialist during study treatment.
Time frame: Day 15 of cycle 1, Day 1 of Cycle 2 and all additional cycles, and 30 (+/- 7) days after last dose (up to 5 years and 2 months)
Phase 1A: Number Of Participants With Abnormal Electrocardiograms
Electrocardiograms were obtained at pre-specified time points. Significant QT interval corrected for heart rate (QTc) prolongation was defined as an interval ≥ 500 milliseconds (msec) or an interval which increases by ≥ 60 msec over baseline.
Time frame: Days 1 and 15 of cycle 1; Day 1 of cycle 2 and all additional cycles; Day 1 of cycle 4; 30 (+/- 7) days after last dose (up to 5 years and 2 months)
Phase 1A: Number Of Participants With Abnormal Laboratory Values
Clinical chemistry, hematology, coagulation, and urinalysis were performed at pre-specified time points for Phase 1A. If warranted, additional testing was done, or the relevant tests done more frequently in accordance with institutional guidelines. All participants who had any Grade 3 or Grade 4 laboratory abnormalities at withdrawal from the study were followed up until they had returned to Grade 1 or Grade 2, unless these were not likely to improve due to the underlying disease. Participants experiencing decreases (low) and increases (high) to ≥ Grade 3 are reported.
Time frame: Day -28 (predose), Days 1, 8, and 15 of cycle 1; Days 1 and 15 of cycle 2 and additional cycles; Days 1 and 15 of cycle 4; 30 (+/- 7) days after last dose (up to 5 years and 2 months)
Phase 1A: Number Of Participants Experiencing Severe AEs
All AEs were monitored per the NCI-CTCAE (v 4.03 2010). In addition to performing the CTCAE assessment, the intensity of each AE and serious adverse event (SAE) recorded was assigned to one of the following categories based on the Investigator's clinical judgment: Mild: an event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; moderate: An event that is sufficiently discomforting to interfere with normal everyday activities; severe: An event that prevents normal everyday activities. Severity was a category utilized for rating the intensity of an event and, accordingly, both AEs and SAEs could be assessed as severe.
Time frame: Day -28 through 5 years and 2 months
Phase 1B: Objective Response Rate (ORR)
The ORR was defined as the percentage of participants in the study whose best overall response was either complete response (CR) or partial response (PR) as assessed by investigators based on Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1.
Time frame: Day -28 through 5 years and 2 months
Phase 1A: Area Under The Plasma Concentration-time Curve Within the Dosing Interval (AUC0-tau) For Tislelizumab
Time frame: Cycle 1 Day 1-1 hour pre-dose, End of infusion, 1, 5, 6, 24, and 72 hours post-dose; Day 15 and Cycle 2 Day 1 Pre-dose
Phase 1A: Maximum Observed Plasma Concentration (Cmax) For Tislelizumab
Time frame: Cycle 1 Day 1-1 hour pre-dose, End of infusion, 1, 5, 6, 24, and 72 hours post-dose; Day 15 and Cycle 2 Day 1 Pre-dose
Phase 1A: Time To Maximum Concentration (Tmax) For Tislelizumab
Time frame: Cycle 1 Day 1-1 hour pre-dose, End of infusion, 1, 5, 6, 24, and 72 hours post-dose; Day 15 and Cycle 2 Day 1 Pre-dose
Phase 1A: Half-life (T½) For Tislelizumab
Time frame: Cycle 1 Day 1-1 hour pre-dose, End of infusion, 1, 5, 6, 24, and 72 hours post-dose; Day 15 and Cycle 2 Day 1 Pre-dose
Phase 1A - Part 3: Clearance (Cl) For Tislelizumab
Time frame: Cycle 1 Day 1-1 hour pre-dose, End of infusion, 1, 5, 6, 24, and 72 hours post-dose; Day 15 and Cycle 2 Day 1 Pre-dose
Phase 1A/1B: Number Of Participants With Anti-drug Antibodies (ADAs)
Immunogenicity was summarized by the number and percentage of participants who developed detectable treatment-emergent ADAs, which included positive ADAs and neutralizing antibodies (NAb).
Time frame: Day 1 of Cycles 1 through 15
Phase 1A: ORR
The ORR was defined as the percentage of participants in the study whose best overall response was either CR or PR as assessed by investigators based on RECIST v 1.1.
Time frame: Day -28 through 5 years and 2 months
Phase 1A: CR Rate
The CR rate was based on RECIST v 1.1 and the results of Investigator evaluations.
Time frame: Day -28 through 5 years and 2 months
Phase 1A: PR Rate
The PR rate was based on RECIST v 1.1 and the results of Investigator evaluations.
Time frame: Day -28 through 5 years and 2 months
Phase 1A: Stable Disease (SD) Rate
The SD rate was based on RECIST v 1.1 and the results of Investigator evaluations.
Time frame: Day -28 through 5 years and 2 months
Phase 1A: Progression-free Survival (PFS)
PFS was defined as the time from the date of first study dose to disease progression or death whichever occurs first. Participants without an event (no disease progression or death) were censored at the date of "last tumor assessment". Participants with no baseline or post-baseline tumor assessments were censored at Day 1. PFS was based on RECIST v 1.1 and the results of Investigator evaluations.
Time frame: Day -28 through 5 years and 2 months
Phase 1A: Overall Survival (OS)
OS was defined as the time interval between the date of the first study drug dose to the date of death for any cause. Kaplan-Meier methodology was used to estimate OS at various time points. The OS was based on RECIST v 1.1 and the results of Investigator evaluations.
Time frame: Day -28 through 5 years and 2 months
Phase 1A: Duration Of Response (DOR)
DOR for responders (CR or PR) was defined as the time interval between the date of the earliest qualifying response and the date of progressive disease or death for any cause, whichever occurred earlier. For participants who were alive without progression following the qualifying response, DOR was censored on the date of last evaluable tumor assessment or last follow-up for progression of disease. The DOR was based on RECIST v 1.1 and the results of Investigator evaluations.
Time frame: Day -28 through 5 years and 2 months
Phase 1B: Number of Participants Experiencing AEs
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of an investigational product. All AEs were monitored per the NCI-CTCAE (v 4.03 2010).
Time frame: Day -28 through 5 years and 2 months
Phase 1B: Steady State Plasma Trough Concentration Of Tislelizumab
Time frame: Pre-dose, Day 1 Cycle 5 and every other Cycle in the first 6 months, every 4 cycles in the next 6 months, once every 6 months up to end of treatment (up to 5 years and 2 months)
Phase 1B: PFS
PFS was defined as the time from the date of first study dose to disease progression or death whichever occurs first. Participants without an event (no disease progression or death) were censored at the date of "last tumor assessment". Participants with no baseline or post-baseline tumor assessments were censored at Day 1. PFS was based on RECIST v 1.1 and the results of Investigator evaluations.
Time frame: Day -28 through 5 years and 2 months
Phase 1B: Disease Control Rate (DCR)
The DCR was defined as the percentage of participants who achieve CR, PR, and SD based on RECIST v 1.1 in participants with select tumor types.
Time frame: Day -28 through 5 years and 2 months
Phase 1B: Clinical Benefit Rate (CBR)
The CBR was defined as the percentage of participants who achieved CR, PR, and durable SD \[SD ≥24 weeks\] based on RECIST v 1.1 in participants with select tumor types.
Time frame: Day -28 through 5 years and 2 months
Phase 1B: Number Of Participants With Abnormal Physical Examination Values
A complete physical examination, vital signs (SBP, DBP, pulse rate, temperature, and respiratory rate), and weight were performed pre-specified time points for Phase 1B. During the treatment period, symptom-directed physical examinations were performed. If there were no complaints and no abnormal findings from the previous visit for a particular organ system, a physical examination of that organ system was not required.
Time frame: Day -28 (predose), Days 1, 4, 8, and 15 of cycle 1; Day 1 of cycle 2; through 30 (+/- 7) days after last dose up to 5 years and 2 months
Phase 1B: Number Of Participants Experiencing Dose-dependent Toxicity Through Ophthalmology Findings
Ophthalmological examinations (such as eyesight/visual acuity, fundoscopy, slit lamp microscopy, and optical coherence tomography \[or equivalent diagnostic test\]) were performed at pre-specified time points for Phase 1B. Eye exam, visual acuity test, and optical coherence tomography (or equivalent diagnostic test) will be assessed by an appropriate specialist at Screening. Participants dosed underwent subsequent ophthalmologic examinations, a specified in the protocol, by an appropriate specialist during study treatment.
Time frame: Day -28 (predose), Day 1 of cycle 2 and additional cycles, and 30 (+/- 7) days after last dose up to 5 years and 2 months
Phase 1B: Number Of Participants With Abnormal Electrocardiograms
Electrocardiograms were obtained at pre-specified time points. Significant QTc prolongation was defined as an interval ≥ 500 msec or an interval which increases by ≥ 60 msec over baseline.
Time frame: Day -28 (predose), Days 1 and 15 of cycle 1; Day 1 of cycle 2 and additional cycles; 30 (+/- 7) days after last dose up to 5 years and 2 months
Phase 1B: Number Of Participants With Abnormal Laboratory Values
Clinical chemistry, hematology, coagulation, and urinalysis will be performed at pre-specified time points for Phase 1A and Phase 1B respectively. If warranted, additional testing was done, or the relevant tests done more frequently in accordance with institutional guidelines. All participants who had any Grade 3 or Grade 4 laboratory abnormalities at withdrawal from the study were followed up until they had returned to Grade 1 or Grade 2, unless these were not likely to improve due to the underlying disease. Participants experiencing decreases (low) and increases (high) to ≥ Grade 3 are reported.
Time frame: Day -28 (predose), Days 1, 8, and 15 of cycle 1; Day 1 of cycle 2 and additional cycles; 30 (+/- 7) days after last dose up to 5 years and 2 months
Phase 1B: Number Of Participants Experiencing Severe AEs
All AEs were monitored per the NCI-CTCAE (v 4.03 2010). In addition to performing the CTCAE assessment, the intensity of each AE and SAE recorded was assigned to one of the following categories based on the Investigator's clinical judgment: Mild: an event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; moderate: An event that is sufficiently discomforting to interfere with normal everyday activities; severe: An event that prevents normal everyday activities. Severity was a category utilized for rating the intensity of an event and, accordingly, both AEs and SAEs could be assessed as severe.
Time frame: Day -28 through 5 years and 2 months
This study was conducted in 27 centers in 5 countries, enrolled from June 2015 to October 2017 across both Phases, and was initiated in June 2015. After a 5-year period the sponsor decided to close the study as primary and secondary endpoints were met. Participants still on treatment were rolled into a separate long-term extension study (BGB-A317-290-LTE1) to continue treatment.
| Milestone | BGB-A317 Phase 1A - Part 1 - 0.5 mg/kg | BGB-A317 Phase 1A - Part 1 - 2.0 mg/kg | BGB-A317 Phase 1A - Part 1 - 5.0 mg/kg | BGB-A317 Phase 1A - Part 1 - 10.0 mg/kg | BGB-A317 Phase 1A - Part 2 - 2.0 mg/kg | BGB-A317 Phase 1A - Part 2 - 5.0 mg/kg | BGB-A317 Phase 1A - Part 3 - 200.0 mg/kg | BGB-A317 Phase 1B |
|---|---|---|---|---|---|---|---|---|
| Started | 3 | 26 | 26 | 7 | 21 | 20 | 13 | 335 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 26 | 26 | 7 | 21 | 20 | 13 | 335 |
| Withdrew: Death | 2 | 22 | 23 | 7 | 17 | 16 | 10 | 248 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 17 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 30 |
| Withdrew: Study terminated by sponsor | 1 | 3 | 3 | 0 | 3 | 4 | 3 | 37 |
| Withdrew: Logistics | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Rolled into long-term extension study | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of an investigational product. All AEs were monitored per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE version \[v\] 4.03 2010).
| Participants | BGB-A317 Phase 1A |
|---|---|
| Phase 1A: Number of Participants Experiencing Adverse Events (AEs) | 114 |
A complete physical examination, vital signs (systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse rate, temperature, and respiratory rate), and weight were performed pre-specified time points for Phase 1A. During the treatment period, symptom-directed physical examinations were performed. If there were no complaints and no abnormal findings from the previous visit for a particular organ system, a physical examination of that organ system was not required.
| Participants | BGB-A317 Phase 1A |
|---|---|
| At least one postbaseline pulse rate measure ≤ 45 beats per minute (bpm) | 1 |
| At least one postbaseline pulse rate measure ≥ 120 bpm | 6 |
| At least one postbaseline SBP measure ≤ 60 millimeters of mercury (mmHg) | 0 |
| At least one postbaseline SBP measure ≤ 90 mmHg | 9 |
| At least one postbaseline SBP measure ≥ 160 mmHg | 17 |
| At least one postbaseline DBP measure ≥ 100 mmHg | 5 |
Ophthalmological examinations (such as eyesight/visual acuity, fundoscopy, slit lamp microscopy, and optical coherence tomography \[or equivalent diagnostic test\]) were performed at pre-specified time points for Phase 1A. Eye exam, visual acuity test, and optical coherence tomography (or equivalent diagnostic test) will be assessed by an appropriate specialist at Screening. Participants dosed underwent subsequent ophthalmologic examinations, a specified in the protocol, by an appropriate specialist during study treatment.
| Participants | BGB-A317 Phase 1A |
|---|---|
| Phase 1A: Number Of Participants Experiencing Dose-dependent Toxicity Through Ophthalmology Findings | 0 |
Electrocardiograms were obtained at pre-specified time points. Significant QT interval corrected for heart rate (QTc) prolongation was defined as an interval ≥ 500 milliseconds (msec) or an interval which increases by ≥ 60 msec over baseline.
| Participants | BGB-A317 Phase 1A |
|---|---|
| At least 1 postbaseline QT corrected using Fridericia's formula (QTcF) Interval measure of >450 msec | 31 |
| At least 1 postbaseline QTcF Interval measure of > 480 msec | 9 |
| At least 1 postbaseline QTcF Interval measure of > 500 msec | 3 |
| At least 1 postbaseline QTcF Interval measure ≤ 30 msec increase from baseline | 73 |
| At least 1 postbaseline QTcF Interval measure ≤ 30 and ≤ 60 msec increase from baseline | 35 |
| At least 1 postbaseline QTcF Interval measure > 60 msec increase from baseline | 8 |
Clinical chemistry, hematology, coagulation, and urinalysis were performed at pre-specified time points for Phase 1A. If warranted, additional testing was done, or the relevant tests done more frequently in accordance with institutional guidelines. All participants who had any Grade 3 or Grade 4 laboratory abnormalities at withdrawal from the study were followed up until they had returned to Grade 1 or Grade 2, unless these were not likely to improve due to the underlying disease. Participants experiencing decreases (low) and increases (high) to ≥ Grade 3 are reported.
| Participants | BGB-A317 Phase 1A |
|---|---|
| Alanine Aminotransferase: High | 6 |
| Albumin: Low | 11 |
| Alkaline Phosphatase: High | 7 |
| Aspartate Aminotransferase: High | 5 |
| Bilirubin: High | 7 |
| Calcium: Low | 7 |
| Calcium: High | 2 |
| Creatinine: High | 6 |
| Glucose: Low | 5 |
| Glucose: High | 13 |
| Hemoglobin: Low | 6 |
| Leukocytes: Low | 3 |
| Leukocytes: High | 0 |
| Lymphocytes: Low | 22 |
| Lymphocytes: High | 2 |
| Neutrophils: Low | 2 |
| Phosphate: Low | 19 |
| Platelets: Low | 1 |
| Potassium: Low | 21 |
| Potassium: High | 7 |
| Sodium: Low | 8 |
| Sodium: High | 0 |
All AEs were monitored per the NCI-CTCAE (v 4.03 2010). In addition to performing the CTCAE assessment, the intensity of each AE and serious adverse event (SAE) recorded was assigned to one of the following categories based on the Investigator's clinical judgment: Mild: an event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; moderate: An event that is sufficiently discomforting to interfere with normal everyday activities; severe: An event that prevents normal everyday activities. Severity was a category utilized for rating the intensity of an event and, accordingly, both AEs and SAEs could be assessed as severe.
| Participants | BGB-A317 Phase 1A |
|---|---|
| Phase 1A: Number Of Participants Experiencing Severe AEs | 14 |
The ORR was defined as the percentage of participants in the study whose best overall response was either complete response (CR) or partial response (PR) as assessed by investigators based on Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1.
| percentage of participants | BGB-A317 Phase 1B |
|---|---|
| Phase 1B: Objective Response Rate (ORR) | 11.6 (8.41 to 15.57) |
| micrograms/milliliter*day | BGB-A317 Phase 1A - Part 1 - 0.5 mg/kg | BGB-A317 Phase 1A - Part 1 - 2.0 mg/kg | BGB-A317 Phase 1A - Part 1 - 5.0 mg/kg | BGB-A317 Phase 1A - Part 1 - 10.0 mg/kg | BGB-A317 Phase 1A - Part 2 - 2.0 mg/kg | BGB-A317 Phase 1A - Part 2 - 5.0 mg/kg | BGB-A317 Phase 1A - Part 3 - 200.0 mg/kg |
|---|---|---|---|---|---|---|---|
| Phase 1A: Area Under The Plasma Concentration-time Curve Within the Dosing Interval (AUC0-tau) For Tislelizumab | 84.92 ± 35.90 | 332.2 ± 57.33 | 811.8 ± 239.5 | 1916.0 ± 458.5 | 512.1 ± 122.2 | 1219.0 ± 287.4 | 674.7 ± 173.6 |
| micrograms/milliliter | BGB-A317 Phase 1A - Part 1 - 0.5 mg/kg | BGB-A317 Phase 1A - Part 1 - 2.0 mg/kg | BGB-A317 Phase 1A - Part 1 - 5.0 mg/kg | BGB-A317 Phase 1A - Part 1 - 10.0 mg/kg | BGB-A317 Phase 1A - Part 2 - 2.0 mg/kg | BGB-A317 Phase 1A - Part 2 - 5.0 mg/kg | BGB-A317 Phase 1A - Part 3 - 200.0 mg/kg |
|---|---|---|---|---|---|---|---|
| Phase 1A: Maximum Observed Plasma Concentration (Cmax) For Tislelizumab | 13.5 ± 3.80 | 48.3 ± 6.89 | 147.0 ± 50.8 | 278.0 ± 53.7 | 56.8 ± 12.8 | 130.0 ± 29.7 | 77.2 ± 13.9 |
| hours | BGB-A317 Phase 1A - Part 1 - 0.5 mg/kg | BGB-A317 Phase 1A - Part 1 - 2.0 mg/kg | BGB-A317 Phase 1A - Part 1 - 5.0 mg/kg | BGB-A317 Phase 1A - Part 1 - 10.0 mg/kg | BGB-A317 Phase 1A - Part 2 - 2.0 mg/kg | BGB-A317 Phase 1A - Part 2 - 5.0 mg/kg | BGB-A317 Phase 1A - Part 3 - 200.0 mg/kg |
|---|---|---|---|---|---|---|---|
| Phase 1A: Time To Maximum Concentration (Tmax) For Tislelizumab | 3.46 ± 3.12 | 2.39 ± 0.89 | 2.48 ± 0.73 | 2.43 ± 1.83 | 1.57 ± 0.65 | 4.95 ± 15.4 | 1.40 ± 0.82 |
| hours | BGB-A317 Phase 1A - Part 1 - 0.5 mg/kg | BGB-A317 Phase 1A - Part 1 - 2.0 mg/kg | BGB-A317 Phase 1A - Part 1 - 5.0 mg/kg | BGB-A317 Phase 1A - Part 1 - 10.0 mg/kg | BGB-A317 Phase 1A - Part 2 - 2.0 mg/kg | BGB-A317 Phase 1A - Part 2 - 5.0 mg/kg | BGB-A317 Phase 1A - Part 3 - 200.0 mg/kg |
|---|---|---|---|---|---|---|---|
| Phase 1A: Half-life (T½) For Tislelizumab | 10.7 ± 3.90 | 12.9 ± 1.2 | 15.0 ± 14.4 | 14.5 ± 4.04 | 17.1 ± 8.14 | 19.6 ± 7.63 | 16.8 ± 5.50 |
| liters/day | BGB-A317 Phase 1A - Part 3 - 200.0 mg/kg |
|---|---|
| Phase 1A - Part 3: Clearance (Cl) For Tislelizumab | 0.186 (0.135 to 0.256) |
Immunogenicity was summarized by the number and percentage of participants who developed detectable treatment-emergent ADAs, which included positive ADAs and neutralizing antibodies (NAb).
| Participants | BGB-A317 Phase 1A - Part 1 - 0.5 mg/kg | BGB-A317 Phase 1A - Part 1 - 2.0 mg/kg | BGB-A317 Phase 1A - Part 1 - 5.0 mg/kg | BGB-A317 Phase 1A - Part 1 - 10.0 mg/kg | BGB-A317 Phase 1A - Part 2 - 2.0 mg/kg | BGB-A317 Phase 1A - Part 2 - 5.0 mg/kg and BGB-A317 Phase 1B | BGB-A317 Phase 1A - Part 3 - 200.0 mg/kg |
|---|---|---|---|---|---|---|---|
| Phase 1A/1B: Number Of Participants With Anti-drug Antibodies (ADAs) | 1 | 6 | 5 | 1 | 6 | 43 | 3 |
The ORR was defined as the percentage of participants in the study whose best overall response was either CR or PR as assessed by investigators based on RECIST v 1.1.
| percentage of participants | BGB-A317 Phase 1A |
|---|---|
| Phase 1A: ORR | 18.1 (11.57 to 26.33) |
The CR rate was based on RECIST v 1.1 and the results of Investigator evaluations.
| Participants | BGB-A317 Phase 1A |
|---|---|
| Phase 1A: CR Rate | 6 |
The PR rate was based on RECIST v 1.1 and the results of Investigator evaluations.
| Participants | BGB-A317 Phase 1A |
|---|---|
| Phase 1A: PR Rate | 15 |
The SD rate was based on RECIST v 1.1 and the results of Investigator evaluations.
| Participants | BGB-A317 Phase 1A |
|---|---|
| Phase 1A: Stable Disease (SD) Rate | 42 |
PFS was defined as the time from the date of first study dose to disease progression or death whichever occurs first. Participants without an event (no disease progression or death) were censored at the date of "last tumor assessment". Participants with no baseline or post-baseline tumor assessments were censored at Day 1. PFS was based on RECIST v 1.1 and the results of Investigator evaluations.
| months | BGB-A317 Phase 1A |
|---|---|
| Phase 1A: Progression-free Survival (PFS) | 3.5 (2.1 to 3.8) |
OS was defined as the time interval between the date of the first study drug dose to the date of death for any cause. Kaplan-Meier methodology was used to estimate OS at various time points. The OS was based on RECIST v 1.1 and the results of Investigator evaluations.
| months | BGB-A317 Phase 1A |
|---|---|
| Phase 1A: Overall Survival (OS) | 13.6 (9.9 to 17.5) |
DOR for responders (CR or PR) was defined as the time interval between the date of the earliest qualifying response and the date of progressive disease or death for any cause, whichever occurred earlier. For participants who were alive without progression following the qualifying response, DOR was censored on the date of last evaluable tumor assessment or last follow-up for progression of disease. The DOR was based on RECIST v 1.1 and the results of Investigator evaluations.
| months | BGB-A317 Phase 1A |
|---|---|
| Phase 1A: Duration Of Response (DOR) | 14.6 (8.3 to NA) |
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of an investigational product. All AEs were monitored per the NCI-CTCAE (v 4.03 2010).
| Participants | BGB-A317 Phase 1B |
|---|---|
| Phase 1B: Number of Participants Experiencing AEs | 322 |
| micrograms/milliliter | BGB-A317 Phase 1B |
|---|---|
| Non-Small Cell Lung Cancer | 63.9 ± 47.8 |
| Ovarian Cancer | 90.4 ± 66.7 |
| Gastric Cancer | 40.7 ± 91.4 |
| Hepatocellular Carcinoma | 54.4 ± 56.8 |
| Head & Neck Squamous Cell Carcinoma | 77.4 ± 45.8 |
| Esophageal Carcinoma | 57.8 ± 62.4 |
| Triple Negative Breast Cancer | 47.8 ± 78.9 |
| Cholangio Carcinoma | 65.7 ± 47.9 |
| Other Solid Tumors | 80.4 ± 43.5 |
PFS was defined as the time from the date of first study dose to disease progression or death whichever occurs first. Participants without an event (no disease progression or death) were censored at the date of "last tumor assessment". Participants with no baseline or post-baseline tumor assessments were censored at Day 1. PFS was based on RECIST v 1.1 and the results of Investigator evaluations.
| months | BGB-A317 Phase 1B |
|---|---|
| Phase 1B: PFS | 2.1 (2.0 to 2.2) |
The DCR was defined as the percentage of participants who achieve CR, PR, and SD based on RECIST v 1.1 in participants with select tumor types.
| percentage of participants | BGB-A317 Phase 1B |
|---|---|
| Phase 1B: Disease Control Rate (DCR) | 41.2 (35.87 to 46.67) |
The CBR was defined as the percentage of participants who achieved CR, PR, and durable SD \[SD ≥24 weeks\] based on RECIST v 1.1 in participants with select tumor types.
| percentage of participants | BGB-A317 Phase 1B |
|---|---|
| Phase 1B: Clinical Benefit Rate (CBR) | 24.5 (19.97 to 29.45) |
A complete physical examination, vital signs (SBP, DBP, pulse rate, temperature, and respiratory rate), and weight were performed pre-specified time points for Phase 1B. During the treatment period, symptom-directed physical examinations were performed. If there were no complaints and no abnormal findings from the previous visit for a particular organ system, a physical examination of that organ system was not required.
| Participants | BGB-A317 Phase 1B |
|---|---|
| At least one postbaseline pulse rate measure ≤ 45 bpm | 5 |
| At least one postbaseline pulse rate measure ≥ 120 bpm | 26 |
| At least one postbaseline SBP measure ≤ 60 mmHg | 1 |
| At least one postbaseline SBP measure ≤ 90 mmHg | 24 |
| At least one postbaseline SBP measure ≥ 160 mmHg | 30 |
| At least one postbaseline DBP measure ≥ 100 mmHg | 12 |
Ophthalmological examinations (such as eyesight/visual acuity, fundoscopy, slit lamp microscopy, and optical coherence tomography \[or equivalent diagnostic test\]) were performed at pre-specified time points for Phase 1B. Eye exam, visual acuity test, and optical coherence tomography (or equivalent diagnostic test) will be assessed by an appropriate specialist at Screening. Participants dosed underwent subsequent ophthalmologic examinations, a specified in the protocol, by an appropriate specialist during study treatment.
| Participants | BGB-A317 Phase 1B |
|---|---|
| Phase 1B: Number Of Participants Experiencing Dose-dependent Toxicity Through Ophthalmology Findings | 0 |
Electrocardiograms were obtained at pre-specified time points. Significant QTc prolongation was defined as an interval ≥ 500 msec or an interval which increases by ≥ 60 msec over baseline.
| Participants | BGB-A317 Phase 1B |
|---|---|
| At least 1 postbaseline QTcF Interval measure > 450 msec | 84 |
| At least 1 postbaseline QTcF Interval measure > 480 msec | 24 |
| At least 1 postbaseline QTcF Interval measure > 500 msec | 10 |
| At least 1 postbaseline QTcF Interval measure ≤ 30 msec increase from baseline | 241 |
| At least 1 postbaseline QTcF Interval measure >30 and ≤ 60 msec increase from baseline | 67 |
| At least 1 postbaseline QTcF Interval measure > 60 msec increase | 22 |
Clinical chemistry, hematology, coagulation, and urinalysis will be performed at pre-specified time points for Phase 1A and Phase 1B respectively. If warranted, additional testing was done, or the relevant tests done more frequently in accordance with institutional guidelines. All participants who had any Grade 3 or Grade 4 laboratory abnormalities at withdrawal from the study were followed up until they had returned to Grade 1 or Grade 2, unless these were not likely to improve due to the underlying disease. Participants experiencing decreases (low) and increases (high) to ≥ Grade 3 are reported.
| Participants | BGB-A317 Phase 1B |
|---|---|
| Alanine Aminotransferase: High | 21 |
| Albumin: Low | 42 |
| Alkaline Phosphatase: High | 21 |
| Aspartate Aminotransferase: High | 21 |
| Bilirubin: High | 22 |
| Calcium: Low | 12 |
| Calcium: High | 7 |
| Creatinine: High | 20 |
| Glucose: Low | 8 |
| Glucose: High | 32 |
| Hemoglobin: Low | 19 |
| Leukocytes: Low | 8 |
| Leukocytes: High | 1 |
| Lymphocytes: Low | 33 |
| Lymphocytes: High | 2 |
| Neutrophils: Low | 5 |
| Phosphate: Low | 42 |
| Platelets: Low | 3 |
| Potassium: Low | 35 |
| Potassium: High | 4 |
| Sodium: Low | 25 |
| Sodium: High | 1 |
All AEs were monitored per the NCI-CTCAE (v 4.03 2010). In addition to performing the CTCAE assessment, the intensity of each AE and SAE recorded was assigned to one of the following categories based on the Investigator's clinical judgment: Mild: an event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; moderate: An event that is sufficiently discomforting to interfere with normal everyday activities; severe: An event that prevents normal everyday activities. Severity was a category utilized for rating the intensity of an event and, accordingly, both AEs and SAEs could be assessed as severe.
| Participants | BGB-A317 Phase 1B |
|---|---|
| Phase 1B: Number Of Participants Experiencing Severe AEs | 27 |
Collected over Day -28 through 5 years and 2 months. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BGB-A317 Phase 1A | 97/116 (83.6%) | 40/116 (34.5%) | 112/116 (96.6%) |
| BGB-A317 Phase 1B | 249/335 (74.3%) | 131/335 (39.1%) | 302/335 (90.1%) |
| Event | BGB-A317 Phase 1A | BGB-A317 Phase 1B |
|---|---|---|
| PneumoniaInfections and infestations | 4/116 | 16/335 |
| Abdominal painGastrointestinal disorders | 3/116 | 3/335 |
| ColitisGastrointestinal disorders | 3/116 | 2/335 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 3/116 | 1/335 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/116 | 8/335 |
| VomitingGastrointestinal disorders | 2/116 | 6/335 |
| PyrexiaGeneral disorders | 2/116 | 6/335 |
| AscitesGastrointestinal disorders | 2/116 | 4/335 |
| NauseaGastrointestinal disorders | 2/116 | 3/335 |
| Back painMusculoskeletal and connective tissue disorders | 2/116 | 4/335 |
| Event | BGB-A317 Phase 1A | BGB-A317 Phase 1B |
|---|---|---|
| FatigueGeneral disorders | 47/116 | 80/335 |
| NauseaGastrointestinal disorders | 41/116 | 71/335 |
| DiarrhoeaGastrointestinal disorders | 33/116 | 49/335 |
| ConstipationGastrointestinal disorders | 28/116 | 51/335 |
| Back painMusculoskeletal and connective tissue disorders | 26/116 | 40/335 |
| Decreased appetiteMetabolism and nutrition disorders | 20/116 | 74/335 |
| Abdominal painGastrointestinal disorders | 25/116 | 42/335 |
| RashSkin and subcutaneous tissue disorders | 23/116 | 39/335 |
| PruritusSkin and subcutaneous tissue disorders | 21/116 | 38/335 |
| VomitingGastrointestinal disorders | 19/116 | 42/335 |
| Age, Continuous(years) | BGB-A317 Phase 1A - Part 1 - 0.5 mg/kg | BGB-A317 Phase 1A - Part 1 - 2.0 mg/kg | BGB-A317 Phase 1A - Part 1 - 5.0 mg/kg | BGB-A317 Phase 1A - Part 1 - 10.0 mg/kg | BGB-A317 Phase 1A - Part 2 - 2.0 mg/kg | BGB-A317 Phase 1A - Part 2 - 5.0 mg/kg | BGB-A317 Phase 1A - Part 3 - 200.0 mg/kg | BGB-A317 Phase 1B | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 54.7 ± 7.02 | 59.1 ± 11.15 | 57.8 ± 13.32 | 57.1 ± 8.13 | 63.6 ± 10.09 | 62.6 ± 11.14 | 58.4 ± 17.76 | 59.5 ± 11.92 | 59.6 ± 11.96 |
| Age, Customized(Participants) | BGB-A317 Phase 1A - Part 1 - 0.5 mg/kg | BGB-A317 Phase 1A - Part 1 - 2.0 mg/kg | BGB-A317 Phase 1A - Part 1 - 5.0 mg/kg | BGB-A317 Phase 1A - Part 1 - 10.0 mg/kg | BGB-A317 Phase 1A - Part 2 - 2.0 mg/kg | BGB-A317 Phase 1A - Part 2 - 5.0 mg/kg | BGB-A317 Phase 1A - Part 3 - 200.0 mg/kg | BGB-A317 Phase 1B | Total |
|---|---|---|---|---|---|---|---|---|---|
| < 65 Years | 3 | 18 | 16 | 6 | 8 | 11 | 6 | 217 | 285 |
| ≥ 65 Years | 0 | 8 | 10 | 1 | 13 | 9 | 7 | 118 | 166 |
| Sex: Female, Male(Participants) | BGB-A317 Phase 1A - Part 1 - 0.5 mg/kg | BGB-A317 Phase 1A - Part 1 - 2.0 mg/kg | BGB-A317 Phase 1A - Part 1 - 5.0 mg/kg | BGB-A317 Phase 1A - Part 1 - 10.0 mg/kg | BGB-A317 Phase 1A - Part 2 - 2.0 mg/kg | BGB-A317 Phase 1A - Part 2 - 5.0 mg/kg | BGB-A317 Phase 1A - Part 3 - 200.0 mg/kg | BGB-A317 Phase 1B | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 12 | 15 | 4 | 10 | 12 | 5 | 144 | 205 |
| Male | 0 | 14 | 11 | 3 | 11 | 8 | 8 | 191 | 246 |
| Ethnicity (NIH/OMB)(Participants) | BGB-A317 Phase 1A - Part 1 - 0.5 mg/kg | BGB-A317 Phase 1A - Part 1 - 2.0 mg/kg | BGB-A317 Phase 1A - Part 1 - 5.0 mg/kg | BGB-A317 Phase 1A - Part 1 - 10.0 mg/kg | BGB-A317 Phase 1A - Part 2 - 2.0 mg/kg | BGB-A317 Phase 1A - Part 2 - 5.0 mg/kg | BGB-A317 Phase 1A - Part 3 - 200.0 mg/kg | BGB-A317 Phase 1B | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 8 | 10 |
| Not Hispanic or Latino | 3 | 24 | 26 | 7 | 21 | 20 | 13 | 322 | 436 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 5 |
| Race/Ethnicity, Customized(Participants) | BGB-A317 Phase 1A - Part 1 - 0.5 mg/kg | BGB-A317 Phase 1A - Part 1 - 2.0 mg/kg | BGB-A317 Phase 1A - Part 1 - 5.0 mg/kg | BGB-A317 Phase 1A - Part 1 - 10.0 mg/kg | BGB-A317 Phase 1A - Part 2 - 2.0 mg/kg | BGB-A317 Phase 1A - Part 2 - 5.0 mg/kg | BGB-A317 Phase 1A - Part 3 - 200.0 mg/kg | BGB-A317 Phase 1B | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Asian | 0 | 2 | 3 | 0 | 1 | 3 | 1 | 120 | 130 |
| Chinese (enrolled from Taiwan sites) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 61 | 61 |
| Non-Chinese | 0 | 2 | 3 | 0 | 1 | 3 | 1 | 59 | 69 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| White | 3 | 22 | 23 | 7 | 19 | 16 | 11 | 189 | 290 |
| Other | 0 | 2 | 0 | 0 | 1 | 1 | 1 | 18 | 23 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan
Ran from Jun 2015 to primary completion in Aug 2020, 62 months.
Results were first posted in Nov 2021, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tislelizumab